WO2006033700A3 - Her2 antibody composition - Google Patents

Her2 antibody composition Download PDF

Info

Publication number
WO2006033700A3
WO2006033700A3 PCT/US2005/025084 US2005025084W WO2006033700A3 WO 2006033700 A3 WO2006033700 A3 WO 2006033700A3 US 2005025084 W US2005025084 W US 2005025084W WO 2006033700 A3 WO2006033700 A3 WO 2006033700A3
Authority
WO
WIPO (PCT)
Prior art keywords
her2 antibody
composition
antibody composition
disclosed
her2
Prior art date
Application number
PCT/US2005/025084
Other languages
French (fr)
Other versions
WO2006033700A2 (en
Inventor
Yung-Hsiang Kao
Martin Vanderlaan
Original Assignee
Genentech Inc
Yung-Hsiang Kao
Martin Vanderlaan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020197032521A priority Critical patent/KR20190126461A/en
Priority to AU2005287404A priority patent/AU2005287404B2/en
Priority to PL05818254T priority patent/PL1771482T3/en
Priority to SI200531907T priority patent/SI1771482T1/en
Priority to KR1020197008923A priority patent/KR20190035967A/en
Priority to CA2574821A priority patent/CA2574821C/en
Application filed by Genentech Inc, Yung-Hsiang Kao, Martin Vanderlaan filed Critical Genentech Inc
Priority to EP05818254.4A priority patent/EP1771482B1/en
Priority to MX2007000723A priority patent/MX2007000723A/en
Priority to ES05818254.4T priority patent/ES2521140T3/en
Priority to KR1020187022854A priority patent/KR20180091967A/en
Priority to JP2007522579A priority patent/JP2008507520A/en
Priority to UAA200701640A priority patent/UA90480C2/en
Priority to CN2005800319054A priority patent/CN101023100B/en
Priority to RSP20140611 priority patent/RS53594B1/en
Priority to KR1020187000071A priority patent/KR20180004850A/en
Priority to NZ552580A priority patent/NZ552580A/en
Priority to KR1020157009058A priority patent/KR20150043558A/en
Priority to KR1020157034266A priority patent/KR20150140417A/en
Priority to DK05818254.4T priority patent/DK1771482T3/en
Priority to KR1020147003441A priority patent/KR20140032004A/en
Priority to KR1020137015103A priority patent/KR20130079648A/en
Priority to KR1020167021573A priority patent/KR20160096228A/en
Priority to BRPI0513681-4A priority patent/BRPI0513681A/en
Priority to KR1020177012110A priority patent/KR20170054551A/en
Publication of WO2006033700A2 publication Critical patent/WO2006033700A2/en
Publication of WO2006033700A3 publication Critical patent/WO2006033700A3/en
Priority to IL180608A priority patent/IL180608A0/en
Priority to TNP2007000020A priority patent/TNSN07020A1/en
Priority to NO20070989A priority patent/NO341293B1/en
Priority to HK07110819.1A priority patent/HK1102599A1/en
Priority to HRP20141111TT priority patent/HRP20141111T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
PCT/US2005/025084 2004-07-22 2005-07-15 Her2 antibody composition WO2006033700A2 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
KR1020167021573A KR20160096228A (en) 2004-07-22 2005-07-15 Her2 antibody composition
PL05818254T PL1771482T3 (en) 2004-07-22 2005-07-15 Her2 antibody composition
SI200531907T SI1771482T1 (en) 2004-07-22 2005-07-15 Her2 antibody composition
KR1020197008923A KR20190035967A (en) 2004-07-22 2005-07-15 Her2 antibody composition
CA2574821A CA2574821C (en) 2004-07-22 2005-07-15 Her2 antibody composition
NZ552580A NZ552580A (en) 2004-07-22 2005-07-15 Her2 antibody composition
EP05818254.4A EP1771482B1 (en) 2004-07-22 2005-07-15 Her2 antibody composition
MX2007000723A MX2007000723A (en) 2004-07-22 2005-07-15 Her2 antibody composition.
ES05818254.4T ES2521140T3 (en) 2004-07-22 2005-07-15 HER2 antibody composition
KR1020187022854A KR20180091967A (en) 2004-07-22 2005-07-15 Her2 antibody composition
JP2007522579A JP2008507520A (en) 2004-07-22 2005-07-15 HER2 antibody composition
UAA200701640A UA90480C2 (en) 2004-07-22 2005-07-15 HER2 antibody composition exhibiting anticancer activity
CN2005800319054A CN101023100B (en) 2004-07-22 2005-07-15 Her2 antibody composition
RSP20140611 RS53594B1 (en) 2004-07-22 2005-07-15 Her2 antibody composition
KR1020187000071A KR20180004850A (en) 2004-07-22 2005-07-15 Her2 antibody composition
KR1020197032521A KR20190126461A (en) 2004-07-22 2005-07-15 Her2 antibody composition
KR1020157009058A KR20150043558A (en) 2004-07-22 2005-07-15 Her2 antibody composition
KR1020157034266A KR20150140417A (en) 2004-07-22 2005-07-15 Her2 antibody composition
DK05818254.4T DK1771482T3 (en) 2004-07-22 2005-07-15 HER2 antibody composition
KR1020147003441A KR20140032004A (en) 2004-07-22 2005-07-15 Her2 antibody composition
KR1020137015103A KR20130079648A (en) 2004-07-22 2005-07-15 Her2 antibody composition
AU2005287404A AU2005287404B2 (en) 2004-07-22 2005-07-15 HER2 antibody composition
BRPI0513681-4A BRPI0513681A (en) 2004-07-22 2005-07-15 compositions comprising her2 antibody, method, pharmaceutical formulations, polypeptide, antibody and cancer treatment method
KR1020177012110A KR20170054551A (en) 2004-07-22 2005-07-15 Her2 antibody composition
IL180608A IL180608A0 (en) 2004-07-22 2007-01-09 Her2 antibody composition
TNP2007000020A TNSN07020A1 (en) 2004-07-22 2007-01-19 Her2 antibody composition
NO20070989A NO341293B1 (en) 2004-07-22 2007-02-21 HER2 antibody composition, the antibody, a pharmaceutical formulation thereof, and the use of the composition for the manufacture of a medicament for the treatment of HER2-expressing cancer.
HK07110819.1A HK1102599A1 (en) 2004-07-22 2007-10-05 Her2 antibody composition her2
HRP20141111TT HRP20141111T1 (en) 2004-07-22 2014-11-17 Her2 antibody composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59020204P 2004-07-22 2004-07-22
US50/590,202 2004-07-22

Publications (2)

Publication Number Publication Date
WO2006033700A2 WO2006033700A2 (en) 2006-03-30
WO2006033700A3 true WO2006033700A3 (en) 2006-09-21

Family

ID=36090425

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025084 WO2006033700A2 (en) 2004-07-22 2005-07-15 Her2 antibody composition

Country Status (37)

Country Link
US (3) US7560111B2 (en)
EP (1) EP1771482B1 (en)
JP (7) JP2008507520A (en)
KR (14) KR20160096228A (en)
CN (1) CN101023100B (en)
AR (2) AR050353A1 (en)
AU (1) AU2005287404B2 (en)
BR (1) BRPI0513681A (en)
CA (1) CA2574821C (en)
CO (1) CO5720212A1 (en)
CR (1) CR8932A (en)
DK (1) DK1771482T3 (en)
EC (1) ECSP077261A (en)
ES (1) ES2521140T3 (en)
GT (1) GT200500199A (en)
HK (1) HK1102599A1 (en)
HR (1) HRP20141111T1 (en)
IL (1) IL180608A0 (en)
JO (1) JO2984B1 (en)
MA (1) MA28784B1 (en)
MX (1) MX2007000723A (en)
MY (1) MY169272A (en)
NO (1) NO341293B1 (en)
NZ (1) NZ552580A (en)
PA (1) PA8639701A1 (en)
PE (1) PE20060552A1 (en)
PL (1) PL1771482T3 (en)
PT (1) PT1771482E (en)
RS (1) RS53594B1 (en)
RU (1) RU2361880C2 (en)
SI (1) SI1771482T1 (en)
SV (1) SV2006002174A (en)
TN (1) TNSN07020A1 (en)
TW (1) TWI369992B (en)
UA (1) UA90480C2 (en)
WO (1) WO2006033700A2 (en)
ZA (1) ZA200701234B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734795B2 (en) 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
US9255149B2 (en) 2008-05-02 2016-02-09 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Cytotoxic immunoglobulin

Families Citing this family (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7960512B2 (en) * 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
SV2006002143A (en) * 2004-06-16 2006-01-26 Genentech Inc USE OF AN ANTIBODY FOR THE TREATMENT OF CANCER RESISTANT TO PLATINUM
KR20160096228A (en) * 2004-07-22 2016-08-12 제넨테크, 인크. Her2 antibody composition
JO3000B1 (en) * 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
ZA200704796B (en) * 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
ATE425186T1 (en) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw SYNTHETIC IMMUNOGLOBULIN DOMAINS WITH BINDING PROPERTIES MODIFIED IN REGIONS OF THE MOLECULE DIFFERENT FROM THE AREAS DETERMINING COMPLEMENTARITY
EP3698807A1 (en) * 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
AU2006216732C1 (en) * 2005-02-23 2017-07-20 Genentech, Inc. Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
MX2007009963A (en) * 2005-02-24 2007-09-26 Amgen Inc Epidermal growth factor receptor mutations.
PE20070207A1 (en) 2005-07-22 2007-03-09 Genentech Inc COMBINED TREATMENT OF TUMORS THAT EXPRESS HER
SI2573114T1 (en) * 2005-08-10 2016-08-31 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2007090794A1 (en) * 2006-02-10 2007-08-16 Nerviano Medical Sciences S.R.L. Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic
JP2009529331A (en) * 2006-03-10 2009-08-20 マクロジェニクス，インコーポレーテッド Identification and engineering modification of antibodies having mutated heavy chains and methods of use thereof
WO2008105886A2 (en) * 2006-05-26 2008-09-04 Macrogenics, Inc. HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
LT2029173T (en) 2006-06-26 2016-11-10 Macrogenics, Inc. Fc riib-specific antibodies and methods of use thereof
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
WO2008073160A2 (en) * 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
US20080112961A1 (en) * 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
JP5602625B2 (en) 2007-06-26 2014-10-08 エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング Binding substance display
CA2693799A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Use of imidazoquinolines for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
RU2370280C2 (en) * 2007-10-08 2009-10-20 Институт физико-химической биологии им. А.Н.Белозерского METHOD OF HER2/neu ONCOGENE ANTIBODY SUPERPRODUCTION IN PLANT
TWI472339B (en) * 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
ES2654937T3 (en) 2008-04-02 2018-02-15 Macrogenics, Inc. Specific antibodies for the BCR complex and procedures for their use
WO2009123894A2 (en) 2008-04-02 2009-10-08 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
JP2010006705A (en) * 2008-06-13 2010-01-14 Atlas Antibodies Ab Her2 subset
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
JP5986745B2 (en) 2008-07-15 2016-09-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Glycan arrays on PTFE-like aluminum-coated glass slides and related methods
CA2751730A1 (en) * 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris
US20110313137A1 (en) * 2009-02-25 2011-12-22 Dongxing Zha Her2 antibody compositions
US8401035B2 (en) * 2009-07-14 2013-03-19 Level 3 Communications, Llc One way SRS information transmission method
US8064431B2 (en) * 2009-07-14 2011-11-22 Level 3 Communications, Llc One way information transmission method
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
EP2507381A4 (en) 2009-12-04 2016-07-20 Hoffmann La Roche Multispecific antibodies, antibody analogs, compositions, and methods
EP2513148B1 (en) * 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2 antibodies and their uses
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
ME03447B (en) 2010-03-04 2020-01-20 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
EP2558501B1 (en) 2010-04-15 2016-09-07 Alper Biotech, Llc Monoclonal antibodies against her2 antigens, and uses therefor
CA2835489C (en) 2010-05-10 2018-03-06 Chi-Huey Wong Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
AU2011257121A1 (en) 2010-05-27 2013-01-10 Genmab A/S Monoclonal antibodies against HER2
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
US9217039B2 (en) 2010-11-01 2015-12-22 Symphogen A/S Anti-HER3 antibodies and compositions
US10485780B2 (en) 2011-03-14 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of proliferative disorders
CN103796677B (en) 2011-04-20 2019-08-16 健玛保 For the bispecific antibody of HER2 and CD3
CN103857700A (en) 2011-08-26 2014-06-11 梅里麦克制药股份有限公司 Tandem FC bispecific antibodies
DK2766040T3 (en) 2011-10-14 2019-07-22 Hoffmann La Roche Pertuzumab, trastuzumab, docetaxel and carboplatin for the treatment of early breast cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
RU2627185C1 (en) * 2012-03-16 2017-08-03 Коваген Аг New binding molecules with anti-tumour activity
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
ES2546105T3 (en) 2012-04-17 2015-09-18 Arsanis Biosciences Gmbh Cross-reactive antibody against Staphylococcus aureus
ES2431914B2 (en) * 2012-04-27 2014-07-24 Universidad De Cádiz ANTI-HER2 human monoclonal antibody
MX2014014162A (en) * 2012-05-24 2015-02-04 Hoffmann La Roche Multispecific antibodies.
EP2858648B1 (en) 2012-06-07 2018-08-22 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
AU2013270684B2 (en) 2012-06-08 2018-04-19 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
WO2014015137A2 (en) * 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
WO2014028446A1 (en) 2012-08-13 2014-02-20 Genentech, Inc. Anti-jagged anitbodies and methods of use
AU2013306098A1 (en) 2012-08-18 2015-02-12 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
WO2014031762A1 (en) 2012-08-21 2014-02-27 Academia Sinica Benzocyclooctyne compounds and uses thereof
HUE045435T2 (en) 2012-10-12 2019-12-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2014070957A1 (en) 2012-10-30 2014-05-08 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
EP2738180A1 (en) * 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
MX363188B (en) 2012-11-30 2019-03-13 Hoffmann La Roche Identification of patients in need of pd-l1 inhibitor cotherapy.
KR20210088741A (en) * 2012-12-13 2021-07-14 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Dna antibody constructs and method of using same
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US9458245B2 (en) 2013-03-06 2016-10-04 Merrimack Pharmaceuticals, Inc. ANTI-C-MET tandem Fc bispecific antibodies
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
BR112015025347A2 (en) 2013-04-09 2017-07-18 Boston Biomedical Inc 2-acetyl naphtho [2-3-b] furan-4,9-dione for use in cancer treatment
AR095863A1 (en) * 2013-04-16 2015-11-18 Genentech Inc VARIATIONS OF PERTUZUMAB, ITS ASSESSMENT, METHOD OF TREATMENT, METHOD OF PREPARATION AND ARTICLE OF MANUFACTURE
EP2994164B1 (en) 2013-05-08 2020-08-05 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
KR101453462B1 (en) 2013-05-16 2014-10-23 앱클론(주) Antibodies Capable of Binding Specifically to HER2
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
CN105682666B (en) 2013-09-06 2021-06-01 中央研究院 Activation of human iNKT cells using glycolipids
WO2015073721A1 (en) 2013-11-13 2015-05-21 Zymeworks Inc. Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
KR101854443B1 (en) 2013-11-19 2018-06-15 레메젠 리미티드 Anti-her2 antibody and conjugate thereof
MX2016006572A (en) 2013-11-27 2016-12-09 Zymeworks Inc Bispecific antigen-binding constructs targeting her2.
JP6510532B2 (en) 2013-12-20 2019-05-08 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Bispecific HER2 antibodies and methods of use
AU2014371934B2 (en) 2013-12-25 2020-01-23 Daiichi Sankyo Company, Limited Anti-TROP2 antibody-drug conjugate
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
EP3973995A1 (en) * 2014-01-31 2022-03-30 Daiichi Sankyo Company, Limited Anti-her2 antibody-drug conjugate
EP3502134B1 (en) 2014-03-11 2020-12-16 Molecular Templates, Inc. Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
JP6856378B2 (en) 2014-03-11 2021-04-07 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. A protein containing the Shiga toxin A subunit effector region and the cell-targeted immunoglobulin-type binding region located proximal to the amino terminus.
CA2943242A1 (en) 2014-03-21 2015-09-24 X-Body, Inc. Bi-specific antigen-binding polypeptides
TWI687428B (en) 2014-03-27 2020-03-11 中央研究院 Reactive labelling compounds and uses thereof
JP6612738B2 (en) 2014-04-10 2019-11-27 第一三共株式会社 Anti-HER2 antibody-drug conjugate
EP3134440A1 (en) 2014-04-25 2017-03-01 F. Hoffmann-La Roche AG Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
US10780182B2 (en) 2014-04-25 2020-09-22 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
AU2015267045B2 (en) 2014-05-27 2021-02-25 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
CN106573971A (en) 2014-05-27 2017-04-19 中央研究院 Anti-CD20 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
EP3149161B1 (en) 2014-05-27 2021-07-28 Academia Sinica Fucosidase from bacteroides and methods using the same
TWI732738B (en) 2014-05-28 2021-07-11 中央研究院 Anti-tnf-alpha glycoantibodies and uses thereof
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
US9968579B2 (en) 2014-07-17 2018-05-15 Beth Isreal Deaconess Medical Center, Inc. ATRA for modulating Pin1 activity and stability
KR101608301B1 (en) 2014-08-22 2016-04-12 앱클론(주) Antibodies Capable of Binding Specifically to HER2
WO2016040369A2 (en) 2014-09-08 2016-03-17 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EA201790545A1 (en) * 2014-09-12 2017-07-31 Дженентек, Инк. ANTIBODIES AND IMMUNOCONJUGATES AGAINST HER2
JP6730261B2 (en) 2014-09-17 2020-07-29 ジェネンテック， インコーポレイテッド Immune complex containing anti-HER2 antibody
CN104225594B (en) * 2014-09-23 2016-03-23 合肥瀚科迈博生物技术有限公司 Anti-HER 2 humanized antibody and relevant anti-tumor compositions thereof
CN107427566B (en) 2014-12-01 2021-08-17 宾夕法尼亚大学理事会 DNA antibody constructs and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
EP3248005B1 (en) 2015-01-24 2020-12-09 Academia Sinica Novel glycan conjugates and methods of use thereof
CN105985435B (en) * 2015-01-30 2019-10-15 嘉和生物药业有限公司 The mutant antibodies and its encoding gene of full source of people HER2 antibody and application
WO2016145186A1 (en) 2015-03-12 2016-09-15 Beth Israel Deaconess Medical Center, Inc. Enhanced atra-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
WO2016168769A1 (en) * 2015-04-15 2016-10-20 The California Institute For Biomedical Research Chimeric receptor t cell switches for her2
EP3294772A4 (en) 2015-05-13 2019-05-01 Zymeworks Inc. Antigen-binding constructs targeting her2
EP3302551A2 (en) 2015-05-30 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating her2-positive locally advanced or previously untreated metastatic breast cancer
CN107849096B (en) 2015-05-30 2022-05-24 分子模板公司 Deimmunized shiga toxin a subunit scaffolds and cell targeting molecules comprising them
TW201717935A (en) 2015-06-03 2017-06-01 波士頓生醫公司 Compositions and methods for treating cancer
KR20180021723A (en) 2015-06-29 2018-03-05 다이이찌 산쿄 가부시키가이샤 Method for selectively manufacturing antibody-drug conjugate
EP3325510A2 (en) 2015-07-26 2018-05-30 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
CN105132357B (en) * 2015-07-29 2019-12-06 苏州诺普再生医学有限公司 serum-free culture system for epidermal cell culture
MX2018002226A (en) 2015-08-28 2018-03-23 Amunix Operating Inc Chimeric polypeptide assembly and methods of making and using the same.
MA44334A (en) 2015-10-29 2018-09-05 Novartis Ag ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
WO2017079694A2 (en) * 2015-11-04 2017-05-11 Priceman Saul J Chimeric antigen receptors targeting her2
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
TWI727380B (en) 2015-11-30 2021-05-11 美商輝瑞股份有限公司 Site specific her2 antibody drug conjugates
TW201808978A (en) 2016-03-08 2018-03-16 中央研究院 Methods for modular synthesis of N-glycans and arrays thereof
RU2648161C2 (en) * 2016-04-01 2018-03-22 Юрий Леонидович Дорохов Method of obtaining the antibody, which specifically binds the domain of the her2/neu excellular part of the her2/neu oncoprotein, in the plant, the antibody, which is obtained by means of this method and its application
MY198114A (en) 2016-04-15 2023-08-04 Macrogenics Inc Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
KR101923624B1 (en) 2016-07-28 2018-11-30 고려대학교 산학협력단 AGTR1 aptamer-anticancer drug complex for cancer cell chemotherapy
JP7213549B2 (en) 2016-08-22 2023-01-27 シーエイチオー ファーマ インコーポレイテッド Antibodies, Binding Fragments, and Methods of Use
CN109862919A (en) 2016-10-11 2019-06-07 免疫医疗有限公司 The therapeutic agent that antibody-drug conjugates combined immunization mediates
JP2019532999A (en) 2016-11-04 2019-11-14 ジェネンテック， インコーポレイテッド Treatment of HER2-positive breast cancer
KR101923641B1 (en) 2016-11-25 2018-11-29 재단법인 목암생명과학연구소 Anti-HER3 antibody and composition for preventing or treating cancer comprising the same
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018110515A1 (en) 2016-12-12 2018-06-21 第一三共株式会社 Combination of antibody-drug conjugate and immune checkpoint inhibitor
CN110099926A (en) 2016-12-28 2019-08-06 豪夫迈·罗氏有限公司 The treatment of advanced stage HER2 expressivity cancer
MX2019008059A (en) 2017-01-17 2019-12-11 Daiichi Sankyo Co Ltd Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate.
RU2750821C2 (en) 2017-01-17 2021-07-05 Дженентек, Инк. Anti-her2 antibody drugs for subcutaneous injection
US11377497B2 (en) 2017-01-23 2022-07-05 Suzhou Alphamab Co., Ltd. PD-L1 binding polypeptide or composite
WO2018140427A1 (en) 2017-01-25 2018-08-02 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
EP3579848A4 (en) 2017-02-08 2021-03-03 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
AU2018220736A1 (en) * 2017-02-20 2019-09-05 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
FI3589661T3 (en) 2017-03-02 2024-01-31 Genentech Inc Adjuvant treatment of her2-positive breast cancer
US11207420B2 (en) 2017-04-19 2021-12-28 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Cytotoxin and conjugate, uses of same and preparation method therefor
CN110536969A (en) 2017-04-24 2019-12-03 豪夫迈·罗氏有限公司 ERBB2/HER2 mutation in cross-film or nearly film domain
AR111651A1 (en) 2017-04-28 2019-08-07 Novartis Ag CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
TWI794230B (en) 2017-05-15 2023-03-01 日商第一三共股份有限公司 Anti cdh6 antibodies and anti cdh6 antibody drug conjugates, as well as manufacturing method thereof
JP2020520923A (en) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド Methods for treating cancer
CN111051330A (en) 2017-08-31 2020-04-21 第一三共株式会社 Improved preparation method of antibody-drug conjugate
US11318212B2 (en) 2017-08-31 2022-05-03 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
CN111132998B (en) 2017-09-25 2024-01-30 苏州丁孚靶点生物技术有限公司 Methods and compositions for cancer treatment
CN111655732B (en) 2017-11-14 2023-09-12 Gc细胞治疗 anti-HER 2 antibodies or antigen binding fragments thereof and chimeric antigen receptors comprising same
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CA3080236A1 (en) 2017-12-15 2019-06-20 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Bioactive molecule conjugate, preparation method and use thereof
CN112368012A (en) 2018-02-08 2021-02-12 蜻蜓疗法股份有限公司 Antibody variable domains targeting NKG2D receptor
TW202003561A (en) 2018-03-13 2020-01-16 瑞士商赫孚孟拉羅股份公司 Combination therapy with targeted 4-1BB (CD137) agonists
EP3773676A4 (en) * 2018-04-03 2022-05-18 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
AR114284A1 (en) 2018-04-13 2020-08-12 Hoffmann La Roche HER2 TARGETING ANTIGEN BINDING MOLECULES COMPOSING 4-1BBL
JP7323200B2 (en) 2018-04-17 2023-08-08 モレキュラー テンプレーツ，インク． HER2 Targeting Molecules Containing Deimmunized Shiga Toxin A Subunit Scaffolds
EP3794041B1 (en) 2018-05-18 2023-07-12 Glycotope GmbH Anti-muc1 antibody
JP2021524449A (en) 2018-05-23 2021-09-13 アーデーセー セラピューティクス ソシエテ アノニム Molecular adjuvant
US20210198370A1 (en) * 2018-05-31 2021-07-01 Board Of Regents, The University Of Texas System Bi-specific antibodies and use thereof
KR20210041586A (en) 2018-08-01 2021-04-15 세파론, 인코포레이티드 Anti-CXCR2 antibodies and uses thereof
RS63865B1 (en) 2018-10-15 2023-01-31 Hoffmann La Roche Methods of treating residual breast cancer with trastuzumab emtansine
WO2020084503A1 (en) 2018-10-26 2020-04-30 Cadila Healthcare Limited A composition comprising antibody with reduced level of basic variants thereof
CN113677403A (en) 2019-04-12 2021-11-19 豪夫迈·罗氏有限公司 Bispecific antigen binding molecules comprising lipocalin muteins
US20220387618A1 (en) 2019-11-15 2022-12-08 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
TW202200618A (en) * 2020-03-17 2022-01-01 美商西雅圖免疫公司 Miniature guidance and navigation control (minignc) antibody-like proteins and methods of making and using thereof
US20220017637A1 (en) 2020-06-23 2022-01-20 Hoffmann-La Roche Inc. Agonistic cd28 antigen binding molecules targeting her2
AU2020456731A1 (en) 2020-06-29 2023-01-05 F. Hoffmann-La Roche Ag Pertuzumab plus trastuzumab fixed dose combination
CA3188134A1 (en) 2020-07-14 2022-01-20 F. Hoffmann-La Roche Ag Assays for fixed dose combinations
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
KR20230145038A (en) 2021-02-09 2023-10-17 메디링크 테라퓨틱스 (쑤저우) 컴퍼니, 리미티드 Bioactive substance conjugate, method of manufacturing same and use thereof
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
KR20240009486A (en) 2021-05-19 2024-01-22 상하이 드 노보 파마테크 컴퍼니 리미티드 Nitrogen-containing compounds, conjugates containing them, and uses thereof
CN117616052A (en) 2021-07-05 2024-02-27 江苏康宁杰瑞生物制药有限公司 Antibody drug conjugate and application thereof
TW202310878A (en) 2021-07-22 2023-03-16 大陸商上海森輝醫藥有限公司 Drug conjugate of eribulin derivative
WO2023158883A2 (en) * 2022-02-19 2023-08-24 Salvitus, Inc. Probiotic vaccines and related methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821337A (en) * 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
WO2001000238A1 (en) * 1999-06-25 2001-01-04 Genentech, Inc. TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
EP1308455A2 (en) * 1998-05-06 2003-05-07 Genentech, Inc. A composition comprising anti-HER2 antibodies
WO2003087131A2 (en) * 2002-04-10 2003-10-23 Genentech, Inc Anti-her2 antibody variants

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH07501451A (en) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド Multivalent antigen binding protein
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
AU687346B2 (en) 1992-06-30 1998-02-26 Oncologix, Inc. A combination of anti-erbB-2 monoclonal antibodies and method of using
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
AU6527894A (en) 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
AU697142B2 (en) 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
ATE163231T1 (en) 1993-11-23 1998-02-15 Genentech Inc KINASE RECEPTOR ACTIVATION TEST
US6287784B1 (en) 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
NZ519191A (en) 1996-10-18 2005-04-29 Univ Texas Antibodies that bind to domain 1 of ErbB2 useful for inducing cell death via apoptosis, and nucleic acids encoding such antibodies
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP0852951A1 (en) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
WO1999048527A1 (en) 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
ATE321066T1 (en) 1998-05-06 2006-04-15 Genentech Inc ANTI-HER2 ANTIBODY COMPOSITION
ES2320311T3 (en) 1999-05-14 2009-05-21 Genentech, Inc. TREATMENT WITH ANTI-ERBB2 ANTIBODIES.
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
EP1189641B1 (en) 1999-06-25 2009-07-29 Genentech, Inc. HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
DE60028970T2 (en) 1999-07-02 2007-02-15 Genentech Inc., San Francisco AT HER2 BINDING PEPTIDE COMPOUNDS
ES2330301T3 (en) 1999-08-27 2009-12-09 Genentech, Inc. DOSAGES FOR TREATMENT WITH ANTI-ERBB2 ANTIBODIES.
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
CN102698265A (en) 2000-05-19 2012-10-03 杰南技术公司 Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US20030190689A1 (en) 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
PT1585966E (en) 2002-07-15 2012-02-20 Hoffmann La Roche Treatment of cancer with the anti-erbb2 antibody rhumab 2c4
BR0214242A (en) * 2002-09-19 2004-09-21 Cristiano Alberto Ribe Santana Product Carrier Composition
WO2004048525A2 (en) * 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
JP4969440B2 (en) 2004-04-08 2012-07-04 デビッド， ビー． エイガス， ErbB antagonist for the treatment of pain
SV2006002143A (en) * 2004-06-16 2006-01-26 Genentech Inc USE OF AN ANTIBODY FOR THE TREATMENT OF CANCER RESISTANT TO PLATINUM
KR20160096228A (en) 2004-07-22 2016-08-12 제넨테크, 인크. Her2 antibody composition
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
ZA200704796B (en) 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
AU2006216732C1 (en) 2005-02-23 2017-07-20 Genentech, Inc. Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
WO2006096861A2 (en) 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
US20070009976A1 (en) 2005-07-06 2007-01-11 Helmut Lenz Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (en) 2005-07-22 2007-03-09 Genentech Inc COMBINED TREATMENT OF TUMORS THAT EXPRESS HER
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
KR20090019890A (en) 2006-06-05 2009-02-25 제넨테크, 인크. Extending survival of cancer patients with elevated levels of egf or tgf-alpha
EP2441472B1 (en) 2006-08-21 2015-06-10 F. Hoffmann-La Roche AG Tumor therapy with an anti-VEGF antibody
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
WO2008109440A2 (en) * 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
TWI472339B (en) * 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821337A (en) * 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
EP1308455A2 (en) * 1998-05-06 2003-05-07 Genentech, Inc. A composition comprising anti-HER2 antibodies
WO2001000238A1 (en) * 1999-06-25 2001-01-04 Genentech, Inc. TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
WO2003087131A2 (en) * 2002-04-10 2003-10-23 Genentech, Inc Anti-her2 antibody variants

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NAHTA R ET AL: "The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 64, no. 7, 1 April 2004 (2004-04-01), pages 2343 - 2346, XP002378994, ISSN: 0008-5472 *
SPIRIDON CAMELIA I ET AL: "Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. JUN 2002, vol. 8, no. 6, June 2002 (2002-06-01), pages 1720 - 1730, XP002389218, ISSN: 1078-0432 *
VAJDOS F F ET AL: "Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 320, no. 2, 5 July 2002 (2002-07-05), pages 415 - 428, XP004449739, ISSN: 0022-2836 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255149B2 (en) 2008-05-02 2016-02-09 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Cytotoxic immunoglobulin
US8734795B2 (en) 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof

Also Published As

Publication number Publication date
CR8932A (en) 2008-04-25
RU2007106725A (en) 2008-08-27
AR111209A2 (en) 2019-06-12
KR20110050567A (en) 2011-05-13
MX2007000723A (en) 2007-03-12
KR20150043558A (en) 2015-04-22
CA2574821A1 (en) 2006-03-30
MA28784B1 (en) 2007-08-01
KR20190126461A (en) 2019-11-11
JP2016104760A (en) 2016-06-09
KR20180004850A (en) 2018-01-12
CA2574821C (en) 2013-07-09
RS53594B1 (en) 2015-02-27
HRP20141111T1 (en) 2015-01-02
TWI369992B (en) 2012-08-11
KR20100101023A (en) 2010-09-15
AR050353A1 (en) 2006-10-18
TNSN07020A1 (en) 2008-06-02
PE20060552A1 (en) 2006-09-06
US20110117097A1 (en) 2011-05-19
ZA200701234B (en) 2008-12-31
JP2017141283A (en) 2017-08-17
AU2005287404B2 (en) 2009-05-07
NO341293B1 (en) 2017-10-02
JP2020079254A (en) 2020-05-28
KR20140032004A (en) 2014-03-13
US20060018899A1 (en) 2006-01-26
EP1771482A2 (en) 2007-04-11
NO20070989L (en) 2007-04-18
GT200500199A (en) 2007-03-23
UA90480C2 (en) 2010-05-11
WO2006033700A2 (en) 2006-03-30
MY169272A (en) 2019-03-21
JP2014208685A (en) 2014-11-06
BRPI0513681A (en) 2008-05-13
PA8639701A1 (en) 2006-07-03
KR20190035967A (en) 2019-04-03
KR20150140417A (en) 2015-12-15
US7560111B2 (en) 2009-07-14
JP2011173914A (en) 2011-09-08
SI1771482T1 (en) 2014-12-31
KR20170054551A (en) 2017-05-17
US8241630B2 (en) 2012-08-14
SV2006002174A (en) 2006-03-06
PL1771482T3 (en) 2015-02-27
HK1102599A1 (en) 2007-11-30
DK1771482T3 (en) 2014-10-20
NZ552580A (en) 2009-08-28
PT1771482E (en) 2014-11-03
TW200616661A (en) 2006-06-01
RU2361880C2 (en) 2009-07-20
CN101023100B (en) 2012-08-29
EP1771482B1 (en) 2014-08-20
IL180608A0 (en) 2007-06-03
CN101023100A (en) 2007-08-22
KR20130079648A (en) 2013-07-10
ES2521140T3 (en) 2014-11-12
US20090285837A1 (en) 2009-11-19
KR20120068807A (en) 2012-06-27
AU2005287404A1 (en) 2006-03-30
US7879325B2 (en) 2011-02-01
KR20160096228A (en) 2016-08-12
JP2008507520A (en) 2008-03-13
ECSP077261A (en) 2007-04-26
CO5720212A1 (en) 2007-01-31
KR20180091967A (en) 2018-08-16
KR20070038557A (en) 2007-04-10
JO2984B1 (en) 2016-09-05
JP2018197258A (en) 2018-12-13

Similar Documents

Publication Publication Date Title
WO2006033700A3 (en) Her2 antibody composition
EA200802170A1 (en) LYOPHILIZED COMPOSITION OF THERAPEUTIC PEPTIDE ANTIBODY
WO2007147001A3 (en) Lyophilized formulations of anti-egfr antibodies
UA104585C2 (en) Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
IL214325A (en) Anti-cmet antibody, composition comprising it and use thereof
WO2006051110A3 (en) Stable formulations of insulinoptropic peptides
IL195338A (en) Antibody comprising an fc variant comprising d or e amino acid substitution at position 239 and pharmaceutical composition and use thereof
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2006044908A3 (en) Antibody formulation in histidine-acetate buffer
MX2009006594A (en) Formulations.
NO2014009I2 (en) Compounds, pharmaceutical compositions and uses thereof, and process for the preparation of said compounds
WO2007115049A3 (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2002030460A3 (en) Therapeutic antibodies
WO2006059234A3 (en) Bicyclic amides as kinase inhibitors
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
WO2006007448A3 (en) Pharmaceutical co-crystal compositions and related methods of use
HK1094167A1 (en) Monoclonal antibodies to hepatocyte growth factor
WO2005123043A3 (en) Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
NO20055209D0 (en) Peptabody for cancer treatment
ATE499939T1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLIBANSERIN POLYMORPHO A
WO2006109303A3 (en) Chimeric proteins comprising yersinia yop, their preparation and pharmaceutical compositions containing them
WO2006110185A3 (en) Antiinfective lipopeptides
WO2006047162A3 (en) Compositions and methods for treatment of disease caused by yersinia spp infection
WO2005048822A3 (en) Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
WO2005105832A3 (en) Biologically active peptide vapeehptllteaplnpk derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 180608

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 552580

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 454/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12007500171

Country of ref document: PH

Ref document number: MX/a/2007/000723

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2574821

Country of ref document: CA

Ref document number: 2007522579

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005818254

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200701234

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: CR2007-008932

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2005287404

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077004108

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20070174

Country of ref document: BY

Ref document number: 2007106725

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2005287404

Country of ref document: AU

Date of ref document: 20050715

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005287404

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200580031905.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020077004108

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005818254

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: DZP2007000033

Country of ref document: DZ

WWP Wipo information: published in national office

Ref document number: 20070174

Country of ref document: BY

ENP Entry into the national phase

Ref document number: PI0513681

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: P-2014/0611

Country of ref document: RS